Impact Factor
4.27
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
6.68
1,804 total citations
h5-index
58
h5 depth signal
Cited share
85.4%
245 of 287
Total citations
1,804
Citation footprint
Metric signal
6.37
External metric anchor
Self-citation
4.8%
87 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
571
United Kingdom
250
Netherlands
197
Germany
194
Canada
140
Citing Fields of Research
Neurodegenerative Disorders
1,483
Neurosciences
169
Postural Control
91
Brain Neurological Disorders
48
Nervous System Disorders
35
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,896
Articles tracked across the journal lifetime
Indexed publication set
287
245 cited publications
Last 12 months
192
16.0 publications/month
Open access share
99.0%
190 OA publications in the last year
Leading citing country
United States
571 citing publications
Leading citing field
Neurodegenerative Disorders
1,483 citing publications
Latest tracked publication
15 October 2026
10 recent records available
Coverage & Indexing History
v1n1, 2011-
v1n1, 2011-
Active Coverage
Research Focus & Classification
Indexed Subjects
Neurodegenerative Disorders
Broad Categories
Neurology
Neurodegenerative Disorders
MeSH Descriptors
Parkinson Disease
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1177/1877718x261497542
Open DOI
GBA1 Canada initiative (G-can), a pre-competitive, open science platform for GBA1 research
GBA1 Canada (G-Can) is a pre-competitive, open-science platform serving as a central hub for basic, translational, and clinical research on GBA1 , which encodes the lysosomal enzyme acid beta-glucocerebrosidase (GCase), a key component o...
02
DOI 10.1177/1877718x261495736
Open DOI
Charting the future: A multi-setting medical chart study of advance care planning in Parkinson's disease and atypical Parkinsonism
Background: Advance Care Planning (ACP) enables people with progressive diseases to document and communicate future treatment preferences. For Parkinson's disease (PD) and atypical parkinsonism (AP), ACP is particularly important because...
03
DOI 10.1177/1877718x261499238
Open DOI
An acoustic-only multivariable diagnostic model for Parkinson's disease using bowel sound acoustic signatures
Background: Early detection of Parkinson's disease (PD) remains challenging due to the lack of reliable prodromal biomarkers. Non-invasive markers of gastrointestinal dysfunction are lacking. Objectives: To characterize bowel sound acous...
04
DOI 10.1177/1877718x261491589
Open DOI
Dopaminergic state modulates shame and contextual emotional responses in Parkinson's disease
Background: Shame is frequent in Parkinson's disease (PD) and negatively affects quality of life, yet its dopaminergic modulation remains unclear. Methods: We investigated the effect of dopaminergic replacement therapy (DRT) on shame in ...
05
DOI 10.1177/1877718x261470565
Open DOI
Technology to remotely capture key elements of swallowing and speech: State of the science in Parkinson's disease
Swallowing and speech impairments are common in Parkinson's disease (PD) and can significantly affect health and quality of life. Traditional methods for assessing and managing these functions rely on in-person visits and large, expensiv...
06
DOI 10.1177/1877718x261494917
Open DOI
Meaningful digital mobility outcomes for people with Parkinson's disease: Insights grounded in diverse lived experience
Background: Digital mobility outcomes (DMOs) have been cited as potential clinical endpoints for trials in Parkinson's disease (PD). Current evidence from the Mobilise-D consortium suggests that selected DMOs are technically valid, with ...
07
DOI 10.1177/1877718x261493297
Open DOI
Considerations for therapeutic targets for clinical trials in biomarker-characterized prodromal Parkinson's disease populations
Parkinson's disease (PD) is a growing public health problem and biologically targeted therapeutics (BTTs) that slow disease progression are urgently needed. However, the development of effective BTTs is challenging as PD is a clinically ...
08
DOI 10.1177/1877718x261480898
Open DOI
Grid to glide: A simple visual cue that alleviates upper-limb freezing
Freezing of the upper limb (FoUL) is a poorly explored manifestation of Parkinson's disease. This report describes a case of a 54-year-old woman with FoUL predominantly affecting handwriting. Writing on grid paper with small squares (0.5...
09
DOI 10.1177/1877718x261480905
Open DOI
Measuring what matters: Evaluating quality of life instruments through the eyes of people with Parkinson's disease
Background: Many instruments are used to assess quality of life in people living with Parkinson's disease. However, there is limited understanding of what people living with Parkinson's consider relevant and important when measuring qual...
10
DOI 10.1177/1877718x261479505
Open DOI
Profiling peripheral immune cells in Parkinson's disease: A scoping review
Parkinson's disease (PD) is increasingly recognized as a multi-system disorder with immune dysregulation extending beyond the central nervous system. Although numerous studies have examined peripheral immune alterations in people with PD...
Bibliographical & Catalog Notes
Also issued online.